Microbix Schedules Release of Results for Q3 Fiscal 2024
August 07 2024 - 6:00AM
Microbix Biosystems Inc. (
TSX: MBX, OTCQX: MBXBF,
Microbix®), a life sciences innovator, manufacturer, and
exporter, announces that it expects to file the financial
statements and management disclosure and analysis for its third
quarter of fiscal 2024 ended June 30, 2024 (“
Q3
2024”) prior to the start of trading on August 14, 2024.
Furthermore, at 10:00 AM ET on that day, Microbix intends to hold a
webinar discussion of Q3 2024 results with its CEO, CFO, and COO.
Investor and shareholders can participate in the
webinar, hosted by Adelaide Capital, by registering at:
https://us02web.zoom.us/webinar/register/WN_s7h8Mb3AQBqCZK34W8krsA.
It will also be live-streamed to YouTube at:
https://www.youtube.com/channel/UC7Jpt_DWjF1qSCzfKlpLMWw.
Telephone participation in the webinar can be
arranged by contacting Microbix or Adelaide Capital at the contact
numbers provided at the end of this news release.
A replay of the webinar will also be made
available on Adelaide Capital’s YouTube channel.
About Microbix Biosystems
Inc.Microbix Biosystems Inc. creates proprietary
biological products for human health, with over 100 skilled
employees and annualized sales now targeting C$ 2.0 million per
month. It makes and exports a wide range of critical ingredients
and devices for the global diagnostics industry, notably antigens
for immunoassays and its laboratory quality assessment products
(QAPs™) that support clinical lab proficiency testing, enable assay
development and validation, or help ensure the quality of clinical
diagnostic workflows. Its antigens drive the antibody tests of
approximately 100 diagnostics makers, while QAPs are sold to
clinical lab accreditation organizations, diagnostics companies,
and clinical labs. Microbix QAPs are now available in over 30
countries, supported by a network of international distributors.
Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered,
Australian TGA registered, Health Canada establishment licensed,
and provides CE marked products.
Microbix also applies its biological expertise
and infrastructure to develop other proprietary products and
technologies, most notably Kinlytic® urokinase, a biologic
thrombolytic drug used to treat blood clots, and reagents or media
to support molecular diagnostic testing (e.g., its DxTM™ for
patient-sample collection). Microbix is traded on the TSX and
OTCQX, and headquartered in Mississauga, Ontario, Canada.
Forward-Looking InformationThis
news release includes “forward-looking information,” as such term
is defined in applicable securities laws. Forward-looking
information includes, without limitation, expected timing of
release of financial results, intended discussion of financial
results or the outlook for the business, risks associated with its
financial results and stability, its current or future products,
development projects such as those referenced herein, sales to
foreign jurisdictions, engineering and construction, production
(including control over costs, quality, quantity and timeliness of
delivery), foreign currency and exchange rates, maintaining
adequate working capital and raising further capital on acceptable
terms or at all, and other similar statements concerning
anticipated future events, conditions or results that are not
historical facts. These statements reflect management’s current
estimates, beliefs, intentions, and expectations; they are not
guarantees of future performance. The Company cautions that all
forward looking information is inherently uncertain, and that
actual performance may be affected by many material factors, some
of which are beyond the Company’s control. Accordingly, actual
future events, conditions and results may differ materially from
the estimates, beliefs, intentions, and expectations expressed or
implied in the forward-looking information. All statements are made
as of the date of this news release and represent the Company’s
judgement as of the date of this new release, and the Company is
under no obligation to update or alter any forward-looking
information.
Please visit www.microbix.com or www.sedarplus.ca
for recent Microbix news and filings.
For further information, please contact Microbix
at:
Cameron Groome, CEO(905) 361-8910 |
Jim Currie, CFO(905) 361-8910 |
Deborah Honig, Investor RelationsAdelaide Capital Markets(647)
203-8793 ir@microbix.com |
|
|
|
Copyright © 2024 Microbix Biosystems Inc.
Microbix®, DxTM™, Kinlytic®, & QAPs™ are trademarks of Microbix
Biosystems Inc.
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Dec 2023 to Dec 2024